Compare United Microelectronics Corp (UMC) vs Viatris Inc (VTRS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
United Microelectronics Corp vs Viatris Inc — how do they compare? United Microelectronics Corp trades at $21.15 (market cap $51.00B), while Viatris Inc trades at $17.54 (market cap $19.79B). The key difference: United Microelectronics Corp is far larger — about 2.6× Viatris Inc's market cap, and Viatris Inc pays the higher dividend (2.83%). Which is the better fit depends on your goals.
| UMC | VTRS | |
|---|---|---|
Market Cap | $51.00B | $19.79B |
Sector | Technology | Health |
52-Week High | $28.02 | $17.39 |
52-Week Low | $6.58 | $8.74 |
Enterprise Value | $48.57B | $32.00B |
Dividend Yield | 2.03% | 2.83% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
UMC trades at $21.19, down 0.28% on the day, with a bullish technical signal from oscillators but bearish moving averages. The company reported Q1 2026 EPS of $0.20, beating expectations, and maintains a net income margin of 20.25%. Recent news highlights mass production of silicon photonics ICs and strong June 2026 sales growth of 22.85% year-over-year.
Outlook is supported by earnings beats and specialty technology demand, but risks include valuation above sector peers and competitive pressures. Analysts are mixed with 26.67% buy ratings, suggesting cautious optimism amid solid execution.
Viatris (VTRS) trades at $17.59, up 1.74% today, with a bullish technical signal and consistent earnings beats in recent quarters. The company reported revenue of $14.3B for 2025 but posted a net loss of $3.51B, reflecting margin pressures. Positive pipeline developments include FDA acceptance of a new drug application for fast-acting meloxicam, with a PDUFA date set for December 2026. Cash flow from operations remains strong at $2.32B, supporting debt reduction efforts.
The outlook is mixed: analyst consensus targets $20.00 (13.7% upside), but profitability challenges and high debt levels pose risks. Investment appeal hinges on successful pipeline execution and margin recovery, while competitive and regulatory pressures in the generics market remain key watchpoints for shareholders.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About United Microelectronics Corp
Founded in 1980, United Microelectronics is the world's third-largest dedicated chip foundry, with 7% market share in 2021, according to Gartner, after TSMC and GlobalFoundries. UMC's headquarters are in Hsinchu, Taiwan, and it operates 12 fabs in Taiwan, Mainland China, Japan and Singapore, with additional sales offices in Europe, the U.S. and South Korea. UMC features a diverse customer base including Texas Instruments, MediaTek, Qualcomm, Broadcom, Xilinx and Realtek, supplying a wide range of products applied in communications, display, memory, automotive and more. UMC employs about 20,000 people.
Read more on UMC →About Viatris Inc
Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →
